These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30577324)

  • 21. Therapeutic perspectives on uricases for gout.
    Garay RP; El-Gewely MR; Labaune JP; Richette P
    Joint Bone Spine; 2012 May; 79(3):237-42. PubMed ID: 22366146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
    J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
    Botson JK; Baraf HSB; Keenan RT; Albert J; Masri KR; Peterson J; Yung C; Freyne B; Amin M; Abdellatif A; Soloman N; Edwards NL; Strand V
    Curr Rheumatol Rep; 2022 Jan; 24(1):12-19. PubMed ID: 35167037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a multivariable improvement measure for gout.
    Schlesinger N; Edwards NL; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
    Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.
    Modjinou DV; Krasnokutsky S; Gyftopoulos S; Pike VC; Karis E; Keenan RT; Lee K; Crittenden DB; Samuels J; Pillinger MH
    Clin Rheumatol; 2017 Sep; 36(9):2101-2107. PubMed ID: 28623421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study.
    Albert JA; Hosey T; LaMoreaux B
    Rheumatol Ther; 2020 Sep; 7(3):639-648. PubMed ID: 32720081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegloticase for chronic gout.
    Anderson A; Singh JA
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review.
    Keenan RT; Botson JK; Masri KR; Padnick-Silver L; LaMoreaux B; Albert JA; Pillinger MH
    Semin Arthritis Rheum; 2021 Apr; 51(2):347-352. PubMed ID: 33601190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resolution of gouty tophi after twelve weeks of pegloticase treatment.
    Baraf HS; Matsumoto AK; Maroli AN; Waltrip RW
    Arthritis Rheum; 2008 Nov; 58(11):3632-4. PubMed ID: 18975338
    [No Abstract]   [Full Text] [Related]  

  • 33. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Khanna PP; Khanna D; Cutter G; Foster J; Melnick J; Jaafar S; Biggers S; Rahman AKMF; Kuo HC; Feese M; Kivitz A; King C; Shergy W; Kent J; Peloso PM; Danila MI; Saag KG
    Arthritis Rheumatol; 2021 Aug; 73(8):1523-1532. PubMed ID: 33750034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
    Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 39. Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy - a study using dual-energy computed tomography.
    Chui CSK; Choi AKY; Lam MMY; Kwan TH; Li OC; Leng Y; Chow DLY
    Mod Rheumatol; 2021 Jul; 31(4):875-884. PubMed ID: 32946311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
    Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.